Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Sara Lonardi et al.|The Lancet Oncology|2016Cited by 1k
Interleukin 10 Increases CCR5 Expression and HIV Infection in Human MonocytesSilvano Sozzani, Alberto Mantovani, Silvia Ghezzi et al.|The Journal of Experimental Medicine|1998Cited by 232